Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Were starting to get some nice volume
Exciting. Submission with US FDA is next
Let's do it, from PA
Covid-19 $AGNPF up 24% today. It's your 2020 Covid play of the year
$AGNPF up 24% today. It's your 2020 Covid play of the year
Nice 24% gain today! I have no doubt Algernon will play a part in the early covid treatment process. Much needed to get the world and economy back on the road to normal
Solod buying pressure.. this is getting ready to breakout. Calm before the storm.
Good to see funds buying....
Ya know what would be nice....some news today
$AGNPF is your Covid Candidate.
They have a safe, repurposed drug that will soon start testing in clinical trials.
$AGNPF is your Covid Candidate.
They have a safe, repurposed drug that will soon start testing in clinical trials
Betting we get updates Monday. I need updates!!!
Ha, the interest is stemming because the company is uniquely positioned to be a substantial player in the Covid-19 arena.
They have a *strong* hypothesis and trials are imminent. All we can do in the near term is await the data.
Data will be everything,
Based on the science I've seen to date it should be favorable.
$AGNPF The Biggest Market Opportunity Of 2020: Coronavirus
Watch closely folks.
https://www.marketwatch.com/press-release/the-biggest-market-opportunity-of-2020-coronavirus-2020-04-17-11197752?mod=mw_quote_news
$AGNPF highlighted in MIT Technology Review
$AGNPF highlighted in MIT Technology Review
Creating new drugs is a laborious process. It takes on average about 10 years to bring a new medicine to market, and even a rushed coronavirus vaccine is likely to take 12 to 18 months. Medicines that have already been tested in humans are already known not to be toxic; the only question is whether they work against covid-19 too. That means pharmaceutical companies can immediately put them into clinical trials. That’s what Algernon Pharmaceuticals, based in Vancouver, Canada, is doing, says CEO Christopher Moreau. Currently, they are investigating the potential of ifenprodil, a drug used to treat circulatory and neurological conditions. If successful, it could be mass distributed in eight to 10 months.
https://www.technologyreview.com/2020/04/15/999481/repurposing-drugs-might-help-fight-coronavirus-pandemic/
$AGNPF on high watch Monday. Covid-19 Play.
Best Penny Stocks To Watch For Coronavirus: Algernon Pharmaceuticals Inc.
https://pennystocks.com/featured/2020/04/17/3-best-penny-stocks-to-watch-coronavirus-update-1-to-avoid-april-17-2020/
$AGNPF on high watch Monday. Covid-19 Play.
Best Penny Stocks To Watch For Coronavirus: Algernon Pharmaceuticals Inc.
https://pennystocks.com/featured/2020/04/17/3-best-penny-stocks-to-watch-coronavirus-update-1-to-avoid-april-17-2020/
Not sure if this has been posted yet but...
https://www.technologyreview.com/2020/04/15/999481/repurposing-drugs-might-help-fight-coronavirus-pandemic/
From MIT Technology ReviewL
This would be more meaningful if it were Monday and the market was open.
Looking forward to a big weeks of news coming. Doubled my share position from mid week. I know nobody cares about my share position and people and this board are probably laughing at its puny size but it makes me feel good updating you folks, so I'll continue to do so.
Expecting a news drop early in the week of South Koren trails getting the green light. Once we get the green light it's all about the data so sit back and buckle up, let's ride folks!
56k shares now still looking to build my position. Remdesivir should bring out the covid-19 craze, hoping for good news tomorrow and a ramp
The big picture surly involves lots of upside for any biotech company, but also lots of risks. See *all* of the big picture not just the rosy picture where 100% of everything goes right.
Woah, I am anything but shor,t in the last two days I've built up a 35000+ share position and willing at least double that if it drops.
I 100% agree with you that science dictates everything. Technicals, everything else doesn't matter because the science either will or will not win out in the end.
I was earlier just commenting on the BILLION dollar MC response. The volume here is minor, cant even hit 1M shares today. On a .30 cent stocks that's not even $300,000 worth of interest and 10k of that was mine!
I think we are due to shoot up in the next 2-3 months and hoping for the best. But every drug in the universe is being thrown at Covid-19 to see if it has any efficacy and there are lots of hurdles to get thru before this is worth 100s of millions. All I'm saying.
Haven't read it but thanks for sharing. I am very new to the company. I've listened to the biopub webcast twice, read thru the last 300-500 posts on here at least twice, and have done a little more DD but not much.
I have 35000+ shares and lots of powder ready if it drops to close that gap in the .20s I'd love to see it ramp to several dollars. I think 20, 30, 50, 100, even 200% gain is a lock from here in the next two months I'm just not yet sold on a multi-million or billion or what I was originally responding to *BILLIONS* of dollar marketcap yet.
Data will tell the story in the coming weeks. Hoping for the best.
I have a decent amount of shares here but we'll be lucky to see a buck. Jmo
Let's worry about holding .30 a share before we start talking billions
Thanks for all of your fantastic DD. It has been a big help to me and I am sure many others.
$AGNPF is the Covid-19 play to be in! 60% yesterday and getting started. P2 trial initiation SOON.
$AGNPF Covid-19 play....60% yesterday just getting started. Unlike penny P%D's this has REAL SCIENCE behind it.
Trial starting in a few weeks right? This can easily go over $1
Is the webcast 11 or 11:30 EST?
I am ecstatic with today's close at HOD. Hope to test 70's prior to Wednesday...
Next week could be big
TPIV WEDNESDAY WEBCAST TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
Study to commence Q2 2016 at Sloan Kettering Institute
Cancer vaccine and checkpoint inhibitor combination to be evaluated in platinum-resistant ovarian cancer patients
TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today plans to initiate a Phase 2 trial of its cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine (FRa), in combination with Astra Zeneca (AZN) durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. The study will commence in the second quarter of 2016 at Memorial Sloan Kettering Cancer Center in New York and will be led by Jason Konner, M.D. as Principal Investigator.
The two Companies will share clinical costs, while TapImmune will supply TPIV 200 and MedImmune will supply Durvalumab (MED14736) for the trials. TapImmune recently obtained Orphan Drug Designation for TPIV 200 in ovarian cancer from the U.S. Food and Drug Administration.
This single arm Phase 2 trial will include 40 women with high-grade ovarian, tubal, or primary peritoneal carcinomas, who have progressed within 6 months of their most recent platinum chemotherapy. The primary objective of the study is to determine the effectiveness of the combination by measuring Overall Response Rate [ORR = Complete Response (CR) + Partial Response (PR)] by RECIST and Progression Free Survival (PFS) rate at 6 months. Secondary endpoints will be safety and immune and correlation of FRa-specific immune responses with clinical efficacy.
"This collaboration is a significant event for TapImmune," stated Dr. Glynn Wilson, Chairman and CEO of TapImmune. "We are delighted to bring a leading T-cell vaccine platform into this combination study and to work with AstraZeneca/Medimmune and Sloan Kettering in a patient population that is in dire need of an effective treatment."
"This study is part of a larger Phase 2 strategy for TPIV 200 that is designed to greatly increase our understanding of the vaccine while providing clinical evidence of efficacy," Dr. Wilson added.
TPIV WEDNESDAY WEBCAST TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
Study to commence Q2 2016 at Sloan Kettering Institute
Cancer vaccine and checkpoint inhibitor combination to be evaluated in platinum-resistant ovarian cancer patients
TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today plans to initiate a Phase 2 trial of its cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine (FRa), in combination with Astra Zeneca (AZN) durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. The study will commence in the second quarter of 2016 at Memorial Sloan Kettering Cancer Center in New York and will be led by Jason Konner, M.D. as Principal Investigator.
The two Companies will share clinical costs, while TapImmune will supply TPIV 200 and MedImmune will supply Durvalumab (MED14736) for the trials. TapImmune recently obtained Orphan Drug Designation for TPIV 200 in ovarian cancer from the U.S. Food and Drug Administration.
This single arm Phase 2 trial will include 40 women with high-grade ovarian, tubal, or primary peritoneal carcinomas, who have progressed within 6 months of their most recent platinum chemotherapy. The primary objective of the study is to determine the effectiveness of the combination by measuring Overall Response Rate [ORR = Complete Response (CR) + Partial Response (PR)] by RECIST and Progression Free Survival (PFS) rate at 6 months. Secondary endpoints will be safety and immune and correlation of FRa-specific immune responses with clinical efficacy.
"This collaboration is a significant event for TapImmune," stated Dr. Glynn Wilson, Chairman and CEO of TapImmune. "We are delighted to bring a leading T-cell vaccine platform into this combination study and to work with AstraZeneca/Medimmune and Sloan Kettering in a patient population that is in dire need of an effective treatment."
"This study is part of a larger Phase 2 strategy for TPIV 200 that is designed to greatly increase our understanding of the vaccine while providing clinical evidence of efficacy," Dr. Wilson added.
TPIV AstraZeneca (AZN) Beefs Up Immuno-Oncology Pipeline with TapImmune Technology
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / AstraZeneca (AZN), a big pharma leader in immuno-oncology has placed its bets on a cancer vaccine technology from TapImmune (TPIV). Amongst a bevy of partnerships, collaborations, and M&A activity between big pharma and innovative biotechs focused on immunotherapies that treat cancer, TapImmune is getting much deserved attention from its bigger brethren looking to fill their pipelines with the most promising cancer cures.
A joint AstraZeneca-TapImmune Phase 2 ovarian cancer trial will start this quarter at the prestigious Sloan Kettering Institute, according to a press release issued a few days ago. The trial will test a combination therapy which includes TapImmune's TPIV 200, a T-cell cancer vaccine, with AstraZeneca's durvalumab an anti-PD-L1 antibody, in 40 women who have high-grade ovarian cancer and have not been responsive to platinum chemotherapy, currently the standard of care for advanced ovarian cancer.
Orphan Drug designation has already been granted by the FDA to TPIV 200 for ovarian cancer. The companies did not state when investors will hear top line data from this trial, however, the primary endpoint will look at efficacy rates 6 months post-treatment, so we may see results within the next three to four quarters.
With a current market cap of $45 million, Tapimmune is an extremely ripe acquisition target, even if acquired at multiple many times its current trading price. This is wholly justifiable given the company's hot immuno-oncology portfolio. TapImmune would be a very easy and very worthwhile acquisition for AstraZeneca, which is worth about $76 billion and is sitting on $6 billion in cash.
TapImmune is likely being sized up AstraZeneca's competitors, all vying for dominance the in the cancer immunotherapy space, including Roche (RHHBY), Merck (MRK), Johnson & Johnson (JNJ), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and others.
Pricing of recent deals shines a spotlight on how undervalued TapImmune is in the space. Merck recently signed a deal to pay $605 million for Israel-based cCAM Biotherapeutics. $95 million was paid upfront, with the balance of $510 million to come based on milestones, for a company whose lead candidate CM-24 is still in Phase 1. Merck is ready to spend after its drug, Keytruda, a PD-1 blocker got FDA approval for melanoma last year. Merck is also paying $375 million to buy OncoEthix for its Phase 1b drug OTX015, a BET inhibitor. $110 million was delivered up front with $265 million coming to OncoEthix upon completion of milestones. J&J just did a deal with Alligator Biosciences worth $700 million, for Alligator's Phase 1 CD40 targeting drug ADC-1013. Abbvie just did a $665 million deal with Argenx for ARGX-115 which is still in preclinicals.
$33 billion in annual sales by 2022 is projected by Morningstar for immuno-oncology drugs, which are expected to be very-high-margin products. This can hugely impact the profitability of big pharma, making acquisitions of technologies like TapImmune's all the more valuable. Further fueling the fire are the FDA's recent approvals of immuno-oncology drugs Opdivo and Keytruda.
TapImmune has much more to offer than TPIV 200 for ovarian cancer. TPIV 200 is also in a U.S. Department of Defense funded Phase 2 trial for triple negative breast cancer at the world renowned Mayo Clinic. TPIV 100 is headed into Phase 2 for HER2/neu breast cancer. The company's preclinical pipeline also holds promise for some very innovative new vaccines.
Big pharma tapping into TapImmune as an acquisition candidate is likely. Merck Research Laboratories'
Vice President and Therapeutic Area Head of Oncology Early Stage Development, Eric Rubin stated Merck is "scouring the world, looking for immunomodulatory agents." Based on recent M&A activity, Merck is not alone.
TPIV TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 3rd Annual Growth Capital Expo to be held on May 3rd - 5th, 2016 at Caesars Palace in Las Vegas, Nevada.
The Company presentation will be given at 8.00 am on Wednesday, May 4th by Dr. John N. Bonfiglio a TapImmune Board member and Strategic Advisor. Entry into Phase II clinical programs in breast and ovarian cancer will be discussed.
TapImmune management will be available for one-on-one investor meetings. The company's presentation will be webcast through the following link: http://wsw.com/webcast/gce3/.
I disagree. It's just 1 idiot talking to himself in all caps. Nothing to get worked up over.
Wouldnt be the worst thing if they did, tho